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Abstract According to standard practice following referral to
clinical genetics, most high risk breast cancer (BC) patients in
many countries receive face-to-face genetic counseling prior
to BRCA-mutation testing (DNA-intake). We evaluated a nov-
el format by prospective study: replacing the intake consulta-
tionwith telephone, written and digital information sent home.
Face-to-face counseling then followedBRCA-mutation testing
(DNA-direct). One year after BRCA-result disclosure, 108
participants returned long-term follow-up questionnaires, of
whom 59 (55 %) had previously chosen DNA-direct
(intervention) versus DNA-intake (standard practice i.e., con-
trol: 45 %). Questionnaires assessed satisfaction and psycho-
logical distress. All participants were satisfied and 85 % of
DNA-direct participants would choose this procedure again;
10 % would prefer DNA-intake and 5 % were undecided. In
repeated measurements ANOVA, general distress (GHQ-12,
p=0.01) and BC-specific distress (IES-bc, p=0.03) were low-
er in DNA-direct than DNA-intake at all time measurements.
Heredity-specific distress (IES-her) did not differ significantly
between groups. Multivariate regression analyses showed that
choice of procedure did not significantly contribute to either
general or heredity-specific distress. BC-specific distress (af-
ter BC diagnosis) did contribute to both general and heredity-
specific distress. This suggests that higher distress scores
reflected BC experience, rather than the type of genetic diag-
nostic procedure. In conclusion, the large majority of BC pa-
tients that used DNA-direct reported high satisfaction without
increased distress both in the short term, and 1 year after
conclusion of genetic testing.
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Introduction
Patients confronted with a diagnosis of breast cancer (BC) desire
quick answers about their personal situation in light of their risk
of a hereditary predisposition (Salemink et al. 2013). Should a
pathogenic BRCA1/2-mutation be found, BC patients are at an
increased risk of up to 60 % of a second primary BC (Antoniou
et al. 2003; Chen and Parmigiani 2007; King et al. 2003) which
may influence the choice of BC treatment (Trainer et al. 2010).
In addition, these patients are also at a high risk for ovarian
cancer (20–60 % for BRCA1 and 2–20 % for BRCA2
(Antoniou et al. 2003; Chen and Parmigiani 2007; King et al.
2003)) and prophylactic surgery is recommended (Hermsen
et al. 2007). Family cascade screening may identify unaffected
BRCA1/2-mutation carriers with an increased lifetime risk of
40–80 % for BC (Antoniou et al. 2003; Chen and Parmigiani
2007; King et al. 2003). BRCA1/2-mutation carriers are eligible
for yearly BC screening or prophylactic surgery from 25 years of
age (Kurian et al. 2010). Following referral to clinical genetics of
high risk BC patients, current genetic counseling practice in
many countries typically involves a face-to-face counseling ses-
sion with a genetic counselor prior to diagnostic BRCA-testing
(Balmana et al. 2011; Berliner et al. 2013; Robson et al. 2015;
Wham et al. 2010). This may add several weeks to the period of
diagnostic uncertainty regarding BRCA1/2 gene status. We hy-
pothesized that a shorter timeline for providing genetic testing
information might be advantageous for BC patients with con-
cerns about their risk of a hereditary predisposition.
To achieve this, we previously evaluated short-term patient
experiences with a novel format replacing the initial face-to-face
consultation prior to BRCA-mutation testing (usual care, DNA-
intake procedure) by telephone, written and digital information
with a blood drawing kit sent to their home address (DNA-direct
procedure) (Sie et al. 2012, 2014a). In both procedures, BRCA-
results were disclosed in face-to-face consultations by an expe-
rienced genetic counselor, including personalized counseling
and cancer prevention recommendations for both patients and
their families (Sie et al. 2012). Given a free choice between these
procedures, 59 % (95 of 161) of eligible BC patients (p=0.03)
chose the new format of BRCA-mutation testing without prior
face-to-face genetic counseling (DNA-direct), indicating an in-
terest in this new procedure. DNA-direct participants were high-
ly satisfied and showed lower psychological distress several
weeks (median 5 [2–22]) after BRCA-result disclosure than
DNA-intake. This suggests that patients with higher distress
were more likely to opt for initial face-to-face contact prior to
genetic testing and remained more distressed throughout the
procedure (Sie et al. 2014a).
While these short-term results were reassuring, literature
shows different trajectories of change in psychological adjust-
ment after BC diagnosis: while the majority remains even or
stabilizes 1 year post-diagnosis, a small group deteriorates in
mental functioning, steadily declining until reaching a plateau
at 19 months (Helgeson et al. 2004). This trend was shown in
older (>65 years) BC patients, where diminished social sup-
port was predictive of deteriorating quality of life (Ganz et al.
2003). BC patients may also be vulnerable due to family can-
cer history, e.g., deaths of family members diminishing their
social support systems. Family history is often the reason for
referral to genetic services (Nelson et al. 2014). We therefore
sought to determine long-term effects and acceptability of the
novel DNA-direct procedure, in order to assess whether dis-
tress is triggered at a later time.
This study thus compared long-term experiences of BC
patients (satisfaction and psychological distress) between the
novel DNA-direct procedure and usual care (DNA-intake),
measured 1 year after BRCA-result disclosure. We hypothe-
sized that patient satisfaction in both procedures would remain
stable over time (as we observed previously shortly after
BRCA-result disclosure), and that DNA-direct does not induce
increased distress in short- or long-term.
Methods
Participants
The study protocol was previously published (Sie et al. 2012).
In short, following approval by the local medical ethics com-
mittee, all female patients (previously) diagnosed with BC and
referred to the department of Human Genetics at Radboudumc
between August 2011 and February 2012 were eligible
(Fig. 1). Exclusion criteria were psychological problems re-
quiring treatment, difficulty with Dutch text, or known BRCA-
families (being associated with different risks of having the
known family BRCA-mutation, therefore different informa-
tion to provide and considerations to make). To evaluate
whether there was a preference for DNA-direct, BC patients
were free to choose between procedures.
DNA-Direct Procedure
As published previously (Sie et al. 2012, 2014a), in the novel
DNA-direct procedure, patients received telephone (triage call
by a trained medical doctor), written and digital information
(website, educational movie) at home. The triage call (median
9 [5–20] minutes) served to check exclusion criteria primarily
meant for pre-test psychosocial assessment of difficulty with
Dutch text, psychological problems (i.e., current psychological
treatment by counseling and/or medication) or family commu-
nication problems (i.e., self-reported need for guidance) (Fig. 1).
Non-excluded patients were offered the choice of DNA-direct
versus DNA-intake to all participants, without genetic counsel-
ing. Patients choosing DNA-direct received an informational
letter and website with video covering basic information about
BC, heredity and genetic testing, similar to a pre-test
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consultation. A blood drawing kit was included to start BRCA-
mutation testing. Written informed consent for DNA-direct and
family history forms were required before diagnostic testing was
initiated. Telephone or e-mail contact with the physician re-
searcher (AS) was available (used by 14 participants, only re-
garding logistics). All BRCA-results were disclosed in a face-to-
face consultation of 45 min (equal to the pre-test DNA-intake
consultation) by one of five experienced genetic counselors.
Study Procedure
Previous results were published (Sie et al. 2014a) based on 161
responses on baseline (T0) questionnaires. Of these, 95 (59 %)
chose the DNA-direct procedure over DNA-intake, and 146 (n=
87 DNA-direct) returned short-term follow-up (T1) question-
naires sent 2 weeks after BRCA-result disclosure. Mutation
detection rate was equal at 8 % in both groups; processing time
was 1 month shorter in the DNA-direct procedure, hypothesized
to be related to the waiting time until the initial appointment for
an intake consultation as BRCA-mutation testing time did not
differ between groups. Additional long-term follow-up (T2) data
are presented here, collected from questionnaires sent 1 year
after BRCA-result disclosure to previous T1 responders; partici-
pation was voluntary.
Instrumentation
The current paper reports new results of 1 year follow-up (T2),
in which the primary study outcomes were: satisfaction re-
garding choice of procedure (T1/T2), general distress (T0/
T1/T2: GHQ-12 (Goldberg et al. 1997) scale 0–12,
Cronbach’s α in this study=0.84 at T0 / 0.89 at T1 / 0.88 at
Breast cancer patients assessed for 
eligibility (N =  233)
Excluded (n = 42) 
• Difficulty with Dutch text (n = 5) 
• Psychological problems (n = 33) 
• Known BRCA-family (n = 3) 
• Non-BRCA referral (n = 1) 
Declined genetic counseling (n = 11) 
No response at baseline (n = 19) 
• Chose DNA-direct (n = 9) 
• Chose DNA-intake (n = 10) 
Participants offered choice of 
procedure and responded at 
baseline (n = 161) 
Lost to follow-up (n = 8) 
• Death (n = 1) 
• No response (n = 7)
Chose DNA-direct  
(n = 95/161, 59%)
Short term follow-up analyzed
DNA-direct (n = 87)
BRCA-mutation test           
(n = 95/95, 100%) 
• BRCA-mutation carriers     
   (n = 8/95, 8%) 
Chose DNA-intake
(n = 66/161, 41%)
Lost to follow-up (n = 5) 
• Overwhelmed (n = 1) 
• No response (n = 4)
Short term follow-up analyzed
DNA-intake (n = 59)
BRCA-mutation test     
(n = 50/66, 76%) 
• BRCA-mutation  
   carriers (n = 4/50, 8%) 
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 Lost to follow-up (n = 2) 
• No response (n = 2) 
No BRCA-mutation test     
(n = 16/66, 24%) 
1 year follow-up analyzed
DNA-direct (n = 59)
1 year follow-up analyzed
DNA-intake (n = 49)1 
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Fig. 1 Flowchart of patient
inclusion, short term and 1 year
follow-up, procedure proportions
and BRCA-results
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T2) and heredity-specific psychological distress (T0/T1/T2:
IES-her (Horowitz et al. 1979; van der Ploeg et al. 2004) scale
0–75, α=0.93 / 0.94 / 0.95).
Secondary psychological measures were BC-specific dis-
tress (T0/T2: IES-bc (Horowitz et al. 1979; van der Ploeg et al.
2004) α=0.93 / 0.92), global quality of life (T0/T1/T2: select-
ed from EORTC-QLQ-Q30 (Bottomley and Aaronson 2007)
scale 0–100, α=0.85 / 0.84 / 0.91), BC worry (T0/T1/T2:
CWS (Lerman et al. 1994) scale 8–32, α=0.84 / 0.85 /
0.82), risk perception of hereditary BC and 2nd BC (T0/T1/
T2: visual scales 0–100). Other secondary T2 outcomes were:
coping style (shortened TMSI (Ong et al. 1999; van Zuuren
et al. 1996)) categorizing responders as more monitoring (sub-
scaleα=0.69) i.e., actively seeking information about medical
threats, more blunting (subscale α=0.69) i.e., seeking distrac-
tion, or neutral, as used in a previous study (Sie et al. 2013);
and open-ended questions regarding a) perceived causes of
their BC and b) most important aspects for other patients to
know about genetic testing (>10 % reported).
Baseline Differences
In previous analyses (Sie et al. 2014a), significant differences in
baseline (T0) sociodemographic and BC characteristics were
found between DNA-direct and DNA-intake groups (Table 1).
Most importantly, DNA-direct participants reported higher
website use (p=0.01), more prior information by their referring
physician about personal consequences (p=0.004), less prior
information by their referring physician about genetics in general
(p=0.008) and lower decisional conflict i.e., difficulty making a
decision whether to start DNA-testing (p=0.01). Baseline differ-
ences were corrected for statistically as described below.
Data Analysis
Data is presented using descriptive statistics. To compare
DNA-direct versus DNA-intake for each T2 outcome, the un-
paired t-test was used for continuous, Mann–Whitney U test
for ordinal and chi-square/Fisher’s Exact test for nominal/
dichotomous variables. To correct for eight baseline differ-
ences (Table 1), these were included as covariates in repeated
measurements ANOVA used to test for changes over the three
time measurements (T0, T1, T2) between DNA-direct versus
DNA-intake (group) in psychological outcomes (general dis-
tress, heredity-specific distress, BC-specific distress, quality
of life, BC worry and risk perception of hereditary BC and
2nd BC). The same correction was performed in multivariate
regression analyses of non-psychological outcomes showing
univariate differences to determine if such differences persist
after correction. Correlations between distress (T2: general,
Table 1 Relevant baseline
differences (p<0.05) in
sociodemographic and breast
cancer (BC) characteristics for all
BC patients choosing DNA-direct
(novel format) or DNA-intake
(usual care) as evaluated in
previous analyses (Sie et al.
2014a)
Characteristic DNA-direct n=95: N (%) or
median [range] or mean±SD
DNA-intake n=66: N (%) or
median [range] or mean±SD
P
Age at inclusion 49 [23–73] 53 [28–74] 0.10
Age at 1st BC diagnosis 47 [23–71] 49 [28–74] 0.15
Months since last BC 6 [0–247] 6 [0–195] 0.92
BRCA referral criteria
- positive family history 75 (79 %) 53 (80 %) 1.00
- age at BC <40 yrs 29 (31 %) 13 (20 %) 0.15
- ovarian cancer in patient 4 (4 %) 2 (3 %) 1.00
Family characteristics
- mother with BC 17 (18 %) 13 (20 %) 0.84
- sister with BC 17 (18 %) 15 (23 %) 0.55
- age (yrs) youngest with BC 40 [23–62] 42 [26–64] 0.03 *
- children living at home 55 (58 %) 26 (39 %) 0.03 *
Educational level
- high 39 (41 %) 13 (20 %) 0.01 *
- medium 27 (28 %) 25 (38 %)
- low 29 (31 %) 28 (42 %)
Use of BC websites 50 (53 %) 21 (32 %) 0.01 *
Information provided by referring physician
- genetics in general 25 (26 %) 31 (47 %) 0.008 *
- personal consequences 39 (41 %) 13 (20 %) 0.006 *
- outcomes of genetic testing 32 (34 %) 12 (18 %) 0.03 *
Decisional conflict (DCS: 0–100) n=87: 16.2±13.9 n=58: 23.2±10.8 0.001 *
* Statistically significant p<0.05: baseline differences included as covariate in multivariate analyses
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heredity-specific, BC-specific) and choice of procedure (DNA-
direct or DNA-intake), sociodemographic characteristics (T0:
age at inclusion, educational level), BC characteristics (T0: age
at 1st BC diagnosis, months since last BC, BRCA referral
criteria, family characteristics) and psychological variables
(T2: quality of life, coping style, BC worry, risk perception
for heredity and for second BC) were assessed using
Pearson’s correlation coefficients. Characteristics with signifi-
cant correlations were used as independent variables in multiple
backward linear regression analysis for the determinants of each
psychological distress measure. The probability level for statis-
tical significance testing was set at 0.05 (two-tailed). The SPSS
20.0 statistical package was used to analyze the data.
Genetic Counselors’ Experiences
Previously unreported, the five involved genetic counselors
filled in a yes/no checklist after each individual DNA-direct
consultation to determine whether they experienced: 1) good
rapport with the patient, 2) unexpected patient reactions, 3)
need for a follow-up consultation, 4) need for non-standard
psychosocial support, 5) the patient having made an informed
choice to startBRCA-testing, and 6) the retrospective preference
for a pre-test intake consultation. They were also asked for their
general opinions during a joint DNA-direct counselor meeting.
Results
A total of 108 BC patients returned 1 year follow-up (T2)
surveys of whom 59 had previously chosen DNA-direct
(55 %), five of which were identified as BRCA-mutation car-
riers, versus 49 participants who had chosen DNA-intake of
which one was a BRCA-mutation carrier.
Satisfaction with Choice of Procedure
All participants in both groups were satisfied with their choice
of procedure, 75 % strongly so; none reported regret. Most
DNA-direct participants (85 %) would choose this procedure
again (one participant emphasized the benefit of taking action
from home during BC diagnosis/treatment) whereas 10 % now
preferred DNA-intake (one stated it would be more personal to
talk to a genetics professional rather than read information) and
5 % did not know (one clarified dependency on their health at
that time). In DNA-intake, most (80 %) would choose this
procedure again with 10 % emphasizing personal contact, but
16 % now preferred DNA-direct (none clarified) and 4 % did
not know (depending on explanation of the procedure).
Two-thirds (63 %) of DNA-direct versus one-third (31 %,
p=0.001) of DNA-intake reported that their recommended
procedure to another patient would depend on that individual
person: their preferences for personal contact, information
formats, comfort using digital media, questions and worries,
capability of processing information, prior medical knowl-
edge, social support. DNA-direct was specifically recom-
mended by 24 % of DNA-direct and 10 % of DNA-intake
participants (one felt the choice could also be made using
DNA-direct, one would recommend DNA-intake instead if
the person had many worries). DNA-intake was recommend-
ed by 9 % of DNA-direct (one mentioned the ability to ask
questions) and 57 % of DNA-intake (one emphasized their
own preference for face-to-face contact). Five percent of
DNA-direct and 2 % of DNA-intake participants were uncer-
tain which procedure to recommend; all stated it was a per-
sonal choice.
Psychological Distress
As shown in Table 2, nomain effects for time (within subjects)
were found for any psychological distress measure. In DNA-
direct, lower scores were reported for general distress than
DNA-intake (GHQ-12: p=0.01, between subjects). Notably,
a near-significant interaction effect between time and choice
of procedure was found (p=0.051): as seen in Fig. 2a, the
difference in general distress between procedures appears
greater at T0 and T1 than at T2. Corrected mean general dis-
tress scores for DNA-intake crossed the threshold for clinical
relevance of GHQ-12≥4 at baseline (Fig. 2a) but dropped
below this threshold after BRCA-result disclosure; no clinical-
ly relevant distress scores were shown in DNA-direct.
Heredity-specific distress (IES-her) did not differ significantly
between procedures, nor showed an interaction effect. BC-
specific distress in DNA-direct did score lower than DNA-
intake (IES-bc: p=0.03) without an interaction effect. All
heredity-specific and BC-specific distress scores remained be-
low the clinical relevance threshold of IES≤26.
Variables significantly correlating with general distress
(GHQ-12), heredity-specific distress (IES-her) or BC-
specific distress (IES-bc) are shown in Table 3. Choice of
procedure (DNA-direct versus DNA-intake) only correlated
to heredity-specific distress, but was no longer significant fol-
lowing multivariate regression analysis. Higher BC-specific
distress was a significant contributor to both general distress
(p=0.01) and heredity-specific distress (p<0.001). General
distress was also more likely in participants with lower quality
of life (p<0.001), while higher heredity-specific distress was
associated with more BC worry (p=0.01) or having a sister
with BC (p=0.02). More BC-specific distress was seen in
those with higher heredity-specific distress (p<0.001), higher
BC worry (p<0.001) or younger age at inclusion (p=0.02).
Secondary Psychological Outcomes
Quality of life, BC worry, risk perception for hereditary BC
and 2nd BC (Table 2) did not differ between DNA-direct
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versus DNA-intake (between subjects) or over time (within
subjects).
Perceived Causes of Breast Cancer
Participants were asked what they thought may have caused
their breast cancer as an open-ended question. As multiple
reasons were possible per responder, percentages are not cu-
mulative: heredity (30 %), bad luck (30 %), stress (14 %) and
hormonal factors e.g., oral contraception (14%) were reported
as perceived causes of BC; 18 % did not know. Only one
significant difference was found: those in the DNA-direct
group were more likely to perceive heredity (e.g., Bit runs in
the family^) as the cause of their BC than in DNA-intake (46
vs. 10 %, p<0.001).
Important Aspects of Genetic Testing
Participants were also asked what they thought was important
to know for other patients who may be eligible for BC genetic
testing as an open-ended question. Responders felt (not cumu-
lative) that these other patients should know about: certainty
and/or clarity about a hereditary predisposition (22 %), con-
sequences for family (18 %), procedural aspects (18 %), con-
sequences of genetic testing (18 %), early prevention (12 %)
and no full guarantees from test results (11 %). No differences
between DNA-direct and DNA-intake were found.
Genetic Counselors’ Experiences
From reports of the DNA-direct disclosure sessions (n=88),
genetic counselors were able to establish good rapport with pa-
tients despite not having spoken to them previously (94 %),
(94 %), experienced few unexpected patient reactions (7 %),
few patients needing follow-up consultations (9 %) or non-
standard psychosocial support (2 %), believed most patients
made an informed choice to start BRCA-testing (76 %) and in
retrospect, did not prefer a pre-test intake consultation for the
majority of patients (85 %). In general, counselors reported the
benefit of to-the-point and personalized counseling, saving time
within the 45 min of a first face-to-face consultation to discuss
personal consequences of the known BRCA-result for the patient
and her family.
Discussion
The current evaluation continues our previous study, which had
already shown that more patients with BC chose the new format
of BRCA-mutation testing without prior face-to-face genetic
counseling (DNA-direct) over the current standard of face-to-
face counseling both prior to and following BRCA-mutation
testing (DNA-intake). Follow-up of these patients showed that
there was no increase in psychological distress at either short- or
long-term. In fact, the DNA-direct participants scored lower on
both general and BC-specific distress than DNA-intake, al-
though distress scores remained below the level of clinical rele-
vance in both groups. We conclude from these study results that
the DNA-direct procedure i.e., face-to-face counseling after
availability of BRCA-mutation testing results, is appropriate es-
pecially for BC patients who are similar to DNA-direct partici-
pants in our study. Patients without pre-existing psychological
problems may prefer to arrange BRCA-mutation testing from
Table 2 Psychological measures for all breast cancer (BC) patients
choosing DNA-direct (novel format, n=59) or DNA-intake (usual care,
n=49) responding at follow-up 1 year post BRCA-result disclosure (T2).
Estimated means±standard deviations are reported following correction
for baseline differences (see Table 1) in repeated measurements ANOVA
Characteristic T0 T1 T2 P*
DNA-direct
n=59
DNA-intake
n=49
DNA-direct
n=59
DNA-intake
n=49
DNA-direct
n=59
DNA-intake
n=49
General distress (GHQ-12: 0–12) 2.7±3.0 4.2±3.5 1.9±3.0 3.9±3.5 1.8±3.0 2.1±3.5 0.01 **
Heredity specific distress (IES-her: 0–75) 13.9±14.5 15.1±14.9 12.3±16.0 14.9±16.2 9.1±12.9 13.4±13.0 0.26
BC-specific distress (IES-bc: 0–75) 17.0±15.7 23.7±15.8 not measured not measured 12.4±14.2 18.1±14.4 0.03
Quality of Life (QoL: 0–100) 73.1±20.0 71.9±20.1 75.0±16.9 73.5±17.3 77.9±19.2 77.7±19.4 0.76
BC worry (CWS: 8–32) 14.1±3.8 15.2±4.0 14.5±3.0 15.2±3.3 13.5±3.8 14.8±3.3 0.10
Risk (0–100) perception: hereditary BC 40.4±24.7 41.1±25.2 32.8±29.9 32.4±30.5 38.6±29.2 38.7±29.8 0.98
Risk (0–100) perception: 2nd BC 45.4±29.2 44.1±29.5 37.7±24.7 41.8±24.9 38.9±28.4 43.2±28.9 0.62
* Reported P-values are associated with the main effect for choice of procedure (DNA-direct versus DNA-intake) in repeated measurements ANOVA:
bold indicates statistical significance p<0.05. No main effects for time (within subjects) were found
** Trend for interaction effect between time and choice of procedure: p=0.051. No other variables showed (trends for) interaction effects
Fig. 2 Changes over time in psychological distress measures: a) general
distress (GHQ-12), b) heredity-specific distress (IES-her), and c) BC-
specific distress (IES-bc). Significant group effects were found only in
general distress (a) and BC-specific distress (c) without significant time
effects in any measure
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home due to reasons associated with their BC diagnosis and
treatment, information needs and preferences, as well as certain
family characteristics (e.g., children living at home). In retro-
spect genetic counselors did not prefer DNA-intake for most
patients (85 %). Counselors emphasized the value of to-the-
point and personalized counseling with more time to discuss
personal consequences rather than general BRCA information.
Counselors also reported that most patients did not require ad-
ditional follow-up (91 %).
One interesting difference at long-term follow-up should be
noted: more DNA-direct participants reported their belief that
heredity (may have) caused their BC, but this was not reflected
in reports of risk perception for hereditary BC, which remained
equal between groups and over time. However, one of the base-
line differences found between groups was that amongst DNA-
direct participants, BC was diagnosed in their family at a youn-
ger age. Although no other clinical variables were previously
found to predict for the choice of DNA-direct (Sie et al.
2014a) this may suggest that these participants are more aware
that their BC risk may still be moderately increased by familial
factors, beyond BRCA-mutations. Risk perceptions for heredi-
tary BC not changing over time for either group is also notable
and in concordance with earlier literature showing that tradition-
al genetic counseling and testing has no lasting effects on risk
perception (Braithwaite et al. 2006; Hilgart et al. 2012).
Improving patient risk perceptions remains a challenge for ge-
netic counseling as a whole, but is not enhanced nor deteriorated
due to the DNA-direct procedure.
However higher uptake of BRCA-testing (100 % in DNA-
direct versus 76 % in DNA-intake) might suggest more
patients were BRCA-tested unnecessarily in DNA-direct:
BRCA-testing was only indicated if one or more of familial
risk scores (e.g., FHAT (Gilpin et al. 2000), Myriad (Frank
et al. 2002), Claus/van Asperen (van Asperen et al. 2004))
exceeded certain thresholds. But familial risk selection criteria
for BRCA-testing were not fulfilled by some patients BRCA-
tested in both groups: 35 % in DNA-direct versus 26 % in
DNA-intake. Mutation detection rate remained equal in both
groups. This reflects that the choice of procedure did not result
in different numbers of patients BRCA-tested, whereas offer-
ing DNA-direct alongside DNA-intake increased patient par-
ticipation and reduced processing time. We consider this to be
the greatest benefit of the DNA-direct procedure.
Study Limitations
As described previously (Sie et al. 2014a), non-randomization
of our study participants limits the ability to argue cause/effect
while non-random sampling limits the generalizability of our
study results. DNA-direct may therefore be most appropriate
for those BC patients matching the overall profile of DNA-
direct participants in our study: those who are higher educated
and better informed, as well as comfortable with or even pre-
ferring different information formats beyond face-to-face con-
tact. We now think that randomization for our study would be
unethical, as our study results suggest a link between distress
and self-selection; although the study limitations remain.
Another study limitation is the low number of BRCA-positive
results which may have influenced our study results, as these
patients are the most likely to experience distress after
Table 3 Determinants of
psychological distress measures
amongst all participating breast
cancer (BC) patients choosing
either DNA-direct (intervention)
or DNA-intake (control),
following correlation testing with
choice of procedure,
sociodemographics, BC
characteristics and other
psychological variables
(significant correlations with
p<0.05 shown)
Characteristic Pearson’s correlation
coefficient
Multivariate regression analysis
P Beta 95 % confidence interval
General distress (GHQ-12)
- Quality of Life (QoL) −0.562 <0.001 −0.544 [−0.114 – -0.063]
- BC-specific distress (IES-bc) 0.255 0.011 0.205 [0.010–0.073]
- BC worry (CWS) 0.275 n.s. – –
- mother with BC −0.363 n.s. – –
- age youngest relative with BC −0.428 n.s. – –
- children living at home 0.196 n.s. – –
Heredity-specific distress (IES-her)
- DNA-direct vs. DNA-intake −0.192 n.s. – –
- BC-specific distress (IES-bc) 0.545 <0.001 0.386 [0.190–0.600]
- BC worry (CWS) 0.520 0.013 0.257 [0.239–1.983]
- sister with BC 0.206 0.022 0.183 [0.929–11.723]
BC-specific distress (IES-bc)
- General distress (GHQ-12) 0.255 n.s. – –
- Heredity-specific distress (IES-her) 0.545 <0.001 0.304 [0.135–0.458]
- BC worry (CWS) 0.631 <0.001 0.452 [1.210–2.618]
- age at inclusion (yrs) −0.233 0.024 −0.165 [−0.411 – -0.030]
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disclosure (Nelson et al. 2014). However, this low number is
reflective of standard clinical genetic practice therefore does
not affect generalizability of our study results. Nearly a third
of our original study cohort did not complete currently report-
ed long-term follow-up measures, which may also have influ-
enced results.
No formal cost-effectiveness analyses have been per-
formed, but DNA-direct reduced face-to-face consultation
time for both genetic counselors and the surrounding re-
sources at the outpatient clinic. The DNA-intake procedure
included a pre-test session of 45 min and a post-test session
of 15 min (total 60 min). The DNA-direct procedure only
included a post-test session of 45 min. We consider such re-
duced consultation and processing times, as well as the in-
creased patient participation of the DNA-direct procedure, to
outweigh cost-effectiveness not formally being proven, de-
pendent on additional BRCA-test costs.
Finally, other events could cause distress in our BC patient
population: time is the only trigger assessed in this study.
However our main interest was the general trend of distress
between the two procedures: other triggers for distress could
be equally present in either group and were not expected to
influence study results.
Practice Implications
Participants who chose the traditional DNA-intake procedure
reported higher general and BC-specific distress, even 1 year
after BRCA-result disclosure. This supports our earlier notion
(Sie et al. 2014a) that distressed patients were more likely to
choose face-to-face counseling prior to genetic testing.
However, choice of procedure did not appear to be a signifi-
cant contributor to general and heredity-specific distress, in-
stead both were associated with BC-specific distress. This
further suggests that higher distress scores were based on the
experience of BC, not the (chosen) genetic diagnostic proce-
dure; and that those who feel more distressed and may be in
need of prior psychosocial support, self-selected to the DNA-
intake procedure where such support was immediately avail-
able. Offering DNA-direct as an alternative to the standard
DNA-intake, to match individual preferences for information
formats prior to BRCA-mutation testing, therefore is consid-
ered acceptable in the light of our follow-up results. This adds
to an ever-growing body of literature (Albada et al. 2011;
Butrick et al. 2014; Metcalfe et al. 2010; Schwartz et al.
2014; Voorwinden et al. 2012) showing that these newmodels
of cancer genetic services varying in combinations of face-to-
face, telephone and/or digital communication, pre- and/or post
BRCA-testing, are acceptable (Trepanier and Allain 2014).
Positive patient experiences with newer multi-gene panels
(Sie et al. 2014b) have currently only been proven after pre-
test counseling regarding possible unsolicited or unclear
findings (Rigter et al. 2014). Therefore we do not currently
recommend DNA-direct for multi-gene panels.
Research Recommendations
Other target groups for DNA-direct may be evaluated. For
example, BRCA-mutations account for 5–16 % of all ovarian
cancer cases (Ramus and Gayther 2009) and guidelines now
recommend referral of all patients with ovarian cancer regard-
less of age or family history (Netherlands 2012). Patients with
ovarian cancer strongly supported genetic testing around the
time of diagnosis (Meiser et al. 2012) and may be excellent
candidates for DNA-direct in the future. Further research may
also focus on alternative service models for the multi-gene
panel setting, starting with those now used for conventional
single-gene testing (Trepanier and Allain 2014).
Conclusions
BC patients who had chosen to forego personal genetic
counseling prior to BRCA-mutation testing, and instead re-
ceive a combination of telephone, written and digital informa-
tion reported high satisfaction and low distress both several
weeks and 1 year after BRCA-result disclosure. Distress in this
population appears to be triggered by the BC diagnosis, not
genetic testing. The novel DNA-direct procedure appears ac-
ceptable for BC patients alongside the traditional face-to-face
intake procedure.
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